Hematology Xagena
RESONATE-2 is a phase 3 study of first-line Ibrutinib ( Imbruvica ) versus Chlorambucil in chronic lymphocytic leukemia ( CLL ) / small lymphocytic lymphoma ( SLL ). Patients aged greater than or ...
The majority of patients with chronic lymphocytic leukemia ( CLL ) are older and have multiple comorbidities, including other cancer diagnoses. These patients are routinely excluded from participation ...
The results from the phase 3 ADMIRAL clinical trial comparing Gilteritinib ( Xospata ) to salvage chemotherapy in adult patients with relapsed or refractory acute myeloid leukemia ( AML ) with a FLT3 ...
Data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months in previously untreated patients with chronic lymphocyti ...
Research from Rutgers Cancer Institute of New Jersey ( Unined States ) has shown improved overall survival at five years for pediatric patients with early-stage Hodgkin lymphoma when treated with chem ...
Patients assigned to Gilteritinib ( Xospata ) were found to have a 36% reduction in risk of death compared with those assigned to standard chemotherapy. Median overall survival was 9.3 months for tho ...
Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only 4 months for relapsed and/or refractory disease. Molecular profiling b ...
The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age wi ...
There are considerable advances in the understanding of the Philadelphia-chromosome (Ph)-negative myeloproliferative neoplasms ( MPN ) in the past 10 years including unraveling the mutation topography ...
Relapse is the major cause of failure after allogeneic stem cell transplantation ( Allo-SCT ) for acute myelogenous leukemia ( AML ). Allo-SCT for high risk acute myelogenous leukemia, defined by ...
Although most patients with relapsed B-cell acute lymphoblastic leukemia ( B-ALL ) experienced complete response after treatment with a type of CAR T-cell immunotherapy, pretreatment disease burden im ...
Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were presented. The study met the key secondary endpoint of overall survival, demons ...
Modern therapy for multiple myeloma including generations of Thalidomide analogues, proteasome inhibitors and alkylating agents has substantially improved the survival for this disease. Patients who ...
Immunotherapy in multiple myeloma is emerging as an effective modality in therapy of multiple myeloma with the approval of several monoclonal antibodies and encouraging results for vaccines and T cell ...
Outcomes of patients with myelodysplastic syndromes ( MDS ) after hypomethylating agent ( HMA ) failure remain poor. Improving the response and survival of patients with higher-risk myelodysplastic sy ...
